CYTOCHROMA ANNOUNCES NEW APPOINTMENTS TO ITS BOARD OF DIRECTORS
MARKHAM, ON, June 13, 2011 /PRNewswire/ - Cytochroma today announced the appointment of Dr. Cynthia Lavoie and Mr. Osamu Otani to its Board of Directors. Dr. Lavoie replaced Dr. Luc Marengère as VG Partners' representative, and Mr. Otani replaced Dr. Seiichi Kiso as Mitsubishi Tanabe Pharma Corporation's representative on the Company's Board. The number of Board members remains unchanged at six members.
"We are pleased to have Cynthia and Osamu join the Cytochroma Board. They bring complementary skills in finance and drug development, which will provide immediate benefits to the Company and position Cytochroma for great success," stated Dr. Alan Lewis, Chairman of Cytochroma's Board of Directors. "We are deeply indebted to Luc and Seiichi for their strong contributions to the Cytochroma Board of Directors and we wish them well."
Dr. Lavoie is a Partner with VG Partners, part of VenGrowth Private Equity Partners Inc., and co-heads the management of the VenGrowth Advanced Life Sciences Fund Inc. She brings over 16 years of experience in research and industry and works closely with Company management lending her technical and financial expertise to operations as well as financing, merger and exit transactions. Dr. Lavoie is currently on the boards of Axela, Interface Biologics, Trillium Therapeutics and Zelos Therapeutics. Her prior experience includes positions as Investment Manager with the Ontario Genomics Institute where she initiated a seed financing program and as Marketing Strategy Consultant with a medical device and therapeutics company.
Mr. Otani joined Tanabe Seiyaku Company Ltd. in 1983, and has served in managerial positions across International Development and Project Management, including General Manager, Tanabe Seiyaku London Office, and Managing Director, Mitsubishi Pharma Research & Development (Beijing). He has been President, Mitsubishi Tanabe Pharma Development America, Inc. since July 2010.
Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism associated with chronic kidney disease (CKD). The Company specializes in developing new therapies which are designed to safely and effectively treat patients with stage 3, 4 or 5 CKD. Cytochroma also has a portfolio CYP24 and phosphate-uptake inhibitors in early stage development.
For more information about Cytochroma, please visit www.cytochroma.com.
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.